I have been on Benicar (olmesartan) HCT for several years. Can you tell me more about this FDA Roadmap Study as it relates to Benicar (olmesartan) and increased risk of cardiovascular death?
Unclear . This was one of many trials that have been conducted with Benicar (olmesartan) which showed a slight increase in mortality among "high risk" diabetic patients (as compared to placebo patients). That said, there was a lot of criticism of these findings - and when additional studies were conducted - the same results were not replicated. Here's a great article: http://www.medscape.com/viewarticle/827288.
Taking Benicar/HCT, and concern about FDA ROADMAP trial study that it increased risk of cardiovascular death. How safe is it and how widely used?
Still safe and used. Benicar (olmesartan) w/ and w/out HCT sells at 8.3 million Rxs/year, and it's in the Top 40 most prescribed. (See Medscape art. #829246.) The most recent info from the FDA was in June 2014; it reported it "found no clear evidence of increased cardiovascular risks." The increased deaths in ROADMAP came mostly in those with the lowest BP. It may be too aggressive BP control rather than the drug is the danger. Read more...